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Abstract: Postprandial hypertriglyceridemia is a potential target for cardiovascular disease
prevention in patients with diabetic dyslipidemia. Metformin has been reported to reduce
plasma triglyceride concentrations in the postprandial states. However, little is known about the
mechanisms underlying the triglyceride-lowering effect of metformin. Here, we examined the
effects of metformin on lipid metabolism after olive oil-loading in 129S mice fed a high fat diet
for three weeks. Metformin administration (250 mg/kg) for one week decreased postprandial
plasma triglycerides. Pre-administration (250 mg/kg) of metformin resulted in a stronger
triglyceride-lowering effect (approximately 45% lower area under the curve) than post-administration.
A single administration (250 mg/kg) of metformin lowered plasma postprandial triglycerides
comparably to administration for one week, suggesting an acute effect of metformin on postprandial
hypertriglyceridemia. To explore whole body lipid metabolism after fat-loading, stomach size, fat
absorption in the intestine, and fat oxidation (13C/12C ratio in expired CO2 after administration of
glyceryl-1-13C tripalmitate) were measured with and without metformin (250 mg/kg) pre-treatment.
In metformin-treated mice, larger stomach size, lower fat oxidation, and no change in lipid absorption
were observed. In conclusion, metformin administration before fat loading reduced postprandial
hypertriglyceridemia, most likely by delaying gastric emptying.
Keywords: Metformin; postprandial hypertriglyceridemia; gastric emptying
1. Introduction
Type 2 diabetes mellitus (T2DM) is a global epidemic [1]. Most individuals with T2DM have
insulin resistance and are at increased risk of developing cardiovascular disease (CVD) [2]. Diabetic
dyslipidemia increases CVD risk [3], especially in subjects with postprandial hypertriglyceridemia [4].
Small chylomicron remnants, generated from chylomicrons in the postprandial state, are recognized as
a risk factor for coronary artery disease [5,6]. Therefore, postprandial dyslipidemia may be a good
target for CVD prevention.
Metformin is the first-line therapy for the pharmacologic treatment of T2DM globally.
Dyslipidemia in the insulin resistant state is characterized by elevated triglyceride (TG) levels
because of increased hepatic very low-density lipoprotein production and impaired clearance of
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very low-density lipoproteins and intestinally-derived chylomicrons by lipoprotein lipase-mediated
lipolysis [7]. In addition to conventional lipid-lowering therapies, such as fibrates, fish oils and statins,
metformin, and pioglitazone are also effective for diabetic dyslipidemia [8–12]. It has been reported
that combination therapy of fenofibrate with metformin reduced TG to a greater extent than fenofibrate
monotherapy [13]. In contrast, pioglitazone had no additional TG-lowering effect when combined
with fenofibrate [14]. These reports suggest that metformin may reduce plasma TG by mechanisms
independent of improved insulin sensitivity. However, little is known regarding the fate of dietary fat
following metformin treatment in vivo. In this study, we explored the mechanisms underlying the
metformin-induced TG-lowering effect, particularly in the postprandial state.
2. Results
2.1. Metformin Treatment for One Week Decreased Postprandial Plasma Glucose Levels without Loss of
Body Weight
To determine the effective doses of metformin on glucose-lowering effect, we administered two
different doses (50 and 250 mg/kg) for one week in mice fed a high-fat diet (HFD) for three weeks.
There were no significant differences in body weight or food intake among the control, 50 mg/kg
metformin treatment and 250 mg/kg metformin treatment groups (Figure 1A,B). After administration
of two different doses of metformin for one week, we performed 1 g/kg oral glucose tolerance tests
(OGTTs) in HFD-fed 129S mice. The 250 mg/kg metformin group displayed significantly lower
plasma glucose concentrations at 15 and 30 min after glucose-loading than those in the control and
50 mg/kg metformin groups (p < 0.01) (Figure 1C). The mean OGTT area under the curve (AUC) in the
250 mg/kg metformin group was approximately 20% lower than those in the other groups (p < 0.01)
(Figure 1D). Based on these results, we selected the 250 mg/kg metformin dose for further evaluation
of lipid metabolism.
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Figure 1. Effects of oral metformin treatment for one week in 129S mice. (A): Body weight change one 
week after metformin treatment (50 and 250 mg/kg); (B) average daily food intake; (C) plasma glucose 
concentration profiles 0–2 h after oral glucose (1.0 g/kg) administration. Metformin (250 mg/kg) was 
administered 1 h before glucose-loading; (D) area under the curve (AUC) for plasma glucose 
concentrations during the oral glucose tolerance test. Filled circle: control group (n = 5); open triangle: 
metformin (50 mg/kg) treatment group (n = 3); open circle: metformin (250 mg/kg) treatment group 
(n = 6) (A–D); (E) plasma triglyceride concentration profiles 0–3 h after oral olive oil (0.4 mL) 
administration. Filled circle: control group (n = 12); open circle: metformin (250 mg/kg) treatment 6 h 
before oral lipid tolerance test (OLTT) group (n = 6); open square: metformin (250 mg/kg) treatment 1 
h before oral lipid tolerance test (OLTT) group (n = 7); (F): AUC for plasma triglyceride concentrations 
during the OLTT. Data represent means ± SE. * p < 0.05, ** p < 0.01, and *** p < 0.001 versus the control 
group. $ p < 0.05 and $$ p < 0.01 versus the metformin (50 mg/kg) treatment group. # p < 0.05 versus the 
metformin (250 mg/kg) treatment 6 h before OLTT group. N.S. indicates not statistically significant. 
2.2. Metformin Treatment for One Week Decreased Postprandial Plasma TG 
Pre-treatment with 250 mg/kg of metformin 6 h before the oral lipid tolerance tests (OLTTs) 
resulted in approximately 60% lower plasma triglyceride concentrations at 120 and 180 min 
compared with those in the control group (p < 0.01) (Figure 1E). Surprisingly, pre-treatment with 250 
mg/kg of metformin 1 h before the OLTTs resulted in no increase in plasma TG levels during the 
OLTTs and the lowest AUC values among the three groups (p < 0.001) (Figure 1F). 
2.3. Both Single and Long-Term Metformin Treatments Decreased Postprandial Plasma TG Levels 
To examine the acute effect of metformin on lipid metabolism, we compared plasma TG 
concentrations between a single treatment and treatment for 1 week. Compared with the control 
group, both the single and one-week metformin groups displayed approximately 70% lower plasma 
TG concentrations 120 min after olive oil-loading (p < 0.001) (Figure 2A,B). 
 
Figure 1. Effects of oral metformin treatment for one week in 129S mice. (A): Body weight change one
week after metformin treatment (50 and 250 mg/kg); (B) average daily food intake; (C) plasma glucose
concentration profiles 0–2 h after oral glucose (1.0 g/kg) administration. Metformin (250 mg/kg)
was administered 1 h before glucose-loading; (D) area under the curve (AUC) for plasma glucose
concentrations during the oral glucose tolerance test. Filled circle: control group (n = 5); open
triangle: metformin (50 mg/kg) treatment group (n = 3); open circle: metformin (250 mg/kg) treatment
group (n = 6) (A–D); (E) plasma triglyceride concentration profiles 0–3 h after oral olive oil (0.4 mL)
administration. Filled circle: control group (n = 12); open circle: metformin (250 mg/kg) treatment 6 h
before oral lipid tolerance test (OLTT) group (n = 6); open square: metformin (250 mg/kg) treatment
1 h before oral lipid tolerance test (OLTT) group (n = 7); (F): AUC for plasma triglyceride concentrations
during the OLTT. Data represent means ± SE. * p < 0.05, ** p < 0.01, and *** p < 0.001 versus the control
group. $ p < 0.05 and $$ p < 0.01 versus the metformin (50 mg/kg) treatment group. # p < 0.05 versus
the metformin (250 mg/kg) treatment 6 h before OLTT group. N.S. indicates not statistically significant.
2.2. Metformin Treatment for One Week Decreased Postprandial Plasma TG
Pre-treatment with 250 mg/kg of metformin 6 h before the oral lipid tolerance tests (OLTTs)
resulted in approximately 60% lower plasma triglyceride concentrations at 120 and 180 min compared
with those in the control group (p < 0.01) (Figure 1E). Surprisingly, pre-treatment with 250 mg/kg of
metformin 1 h before the OLTTs resulted in no increase in plasma TG levels during the OLTTs and the
lowest AUC values among the three groups (p < 0.001) (Figure 1F).
2.3. Both Single and Long-Term Metformin Treatments Decreased Postprandial Plasma TG Levels
To examine the acute effect of metformin on lipid metabolism, we compared plasma TG
concentrations between a single treatment and treatment for 1 week. Compared with the control
group, both the single and one-week metformin groups displayed approximately 70% lower plasma
TG concentrations 120 min after olive oil-loading (p < 0.001) (Figure 2A,B).
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Figure 2. Effects of oral metformin treatment for one week (A,B) and a single metformin treatment
(C–F) in 129S mice; (A) plasma triglyceride concentration profiles 0–2 h after oral olive oil (0.4 mL)
administration. Metformin (250 mg/kg) was administered 1 h before olive oil-loading. Filled circle:
control group; open circle: long-term metformin treatment for one week group; open square: single
metformin treatment group; (B) area under the curve (AUC) for plasma triglyceride concentrations
during the OLTT. Data represent means ± SE. n = 4 mice/group; ** p < 0.01, *** p < 0.001 versus
the control group; (C) plasma triglyceride concentration profiles 0–2 h after oral olive oil (0.4 mL)
administration. Open circle: metformin 1 h pre-treatment group; open square: metformin 0.5 h
post-treatment group; open triangle: metformin simultaneous-treatment group; (D) AUC for plasma
triglyceride concentrations during the OLTT. (E) Plasma glucose concentration profiles 0–2 h after
oral glucose (1 g/kg) administration. Open circle: metformin 1 h pre-treatment group; open square:
metformin 0.5 h post-treatment group; open triangle: metformin simultaneous-treatment group;
(F) AUC for plasma glucose concentrations during oral glucose tolerance tests (OGTTs). Data represent
means ± SE. n = 4 mice/group; * p < 0.05 versus the metformin (250 mg/kg) post-treatment group.
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2.4. A Single Metformin Pre-Treatment Decreased Postprandial Plasma TG Levels Compared
with Post-Treatment
To assess efficacy of the timing of metformin administration for postprandial TG levels, metformin
(250 mg/kg) was administered 1 h before and 0.5 h after olive oil-loading. In contrast to pre-treatment,
post-treatment of metformin displayed a two-fold increase in plasma TG concentrations 60 min
after olive oil-loading (Figure 2C). The simultaneous treatment of metformin resulted in similar
suppression of plasma TG concentrations 60 min after olive-oil loading, but a gradual increase at
120 min (Figure 2C). AUCs in the pre-treatment group were approximately 45% lower than those
in the post-treatment group (p < 0.05) (Figure 2D). In OGTT, single metformin pre-treatment also
significantly lowered plasma glucose concentrations than post-treatment (p < 0.05) (Figure 2E). AUCs
in the pre-treatment group were approximately 40% lower than those in the post-treatment groups
(Figure 2F). The simultaneous treatment of metformin showed intermediate levels of plasma glucose
between post- and pre-treatments (Figure 2E,F).
2.5. Effect of Metformin on Gastric Size during Olive Oil-Loading
To explore the mechanisms underlying the TG-lowering effect of metformin, 129S mice were
sacrificed 3 h after olive oil-loading. Stomach sizes were larger in the 250 mg/kg metformin
pre-treatment group than those in the control group (Figure 3A). Stomach contents were approximately
seven-fold larger in the metformin pre-treatment group, suggesting that gastric emptying was delayed
by metformin treatment (p < 0.001) (Figure 3B).
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e evaluated the fate of lipids following etfor in treat ent using stable isotope labeled fatty
acids. Glyceryl-1-13C tripalmitate was administered to 129S mice as a form of TG with or without 1-h
etfor in pre-treat ent. Ad inistered glyceryl-1-13C tripalmitate are beta oxidized and ultimately
catabolized to 13CO2 in the mitochondria. Thus, changes in the 13C/12C ratio (∆13C) in expired CO2
from mice indicated the degree of whole body beta oxidation. Metformin-treated mice displayed
lower ∆13C increments than those of control mice (mean AUC ∆13Ch, Control, 753.1 ± 61.9 (min*h)
versus Metformin, 112.6 ± 42.1 (min*h), p < 0.001) (Figure 5). This result suggests that metformin
treatment may delay gastric emptying and subsequently reduce glyceryl-1-13C tripalmitate absorption
per unit time.
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3. Discussion
In this study, we identified two novel outcomes of metformin treatment. First, a single
pre-treatment with metformin reduced postprandial hypertriglyceridemia. Second, the mechanism
underlying the TG-lowering effect may be mediated by delayed gastric emptying.
Metformin reduced postprandial hypertriglyceridemia in this study. This is consistent with
previous clinical studies that have shown that metformin reduced plasma TG concentrations in the
fasting and postprandial states [8,9,15–18]. In these studies, metformin treatment for several months
increased insulin sensitivity because of improved long-term glycemic control and reduced body
weight. Improvements in insulin resistance and reductions in body weight increase lipoprotein lipase
activity [19–21], which plays a key role in breaking down plasma TG from TG-rich lipoproteins, such
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as chylomicrons and very low density lipoproteins. Therefore, it is difficult to distinguish the direct
effect from secondary effects due to insulin sensitivity or body weight reduction. The TG-lowering
effect, similar to the glucose-lowering effect, in the fasting state was reported to be dose-dependent [22].
In our animal studies, metformin treatment for one week reduced postprandial TG concentrations
with no change in food consumption or body weight. Surprisingly, we found that a single metformin
treatment had the same TG-lowering effect as metformin treatment for one week.
The mechanism underlying the TG-lowering effect may be through delayed gastric emptying.
Medication efficacy can sometimes vary with the timing of administration relative to food intake.
Meals decreased the bioavailability of metformin, with a 20% lower AUC and 35% lower Cmax, and
delayed the absorption of metformin, with tmax prolonged by nearly 40 min [23]. However, post-meal
administration of metformin is performed to maintain patients’ adherence in the clinical setting.
A recent report revealed that postprandial glucose levels are improved by pre-meal administration
of metformin compared with those following post-meal treatment [24]. Our data demonstrated
that pre-meal treatment of metformin significantly improved both glucose and TG concentrations
compared with post-meal administration (Figure 2C,E). The simultaneous treatment of metformin
showed intermediate suppressions both in glucose and TG concentration, which might be due to
reduced intraluminal concentration of metformin. The fate of dietary fat involves multiple steps,
including gastric emptying, digestion in the intestine, absorption, TG storage in adipose tissue by
lipoprotein lipase and fat oxidation in liver and skeletal muscle. In our study, metformin significantly
reduced postprandial TG levels by delaying gastric emptying (Figure 3). Regulation of gastric emptying
represents the most important brake against nutrient delivery to the intestine, which slows absorption
of nutrients in the small intestine. Several studies have reported that delaying gastric emptying
reduced postprandial glucose concentrations, while the relationship between delayed gastric emptying
and reduced postprandial TG concentrations was unknown [25–27]. To the best of our knowledge, this
study is the first to demonstrate that the acute effect of metformin on postprandial hypertriglyceridemia
is mediated by delayed gastric emptying. The molecular mechanisms underlying this phenomenon
are entirely unknown. Further studies are necessary to elucidate the mechanisms and confirm this
concept in human subjects.
Three limitations should be noted. First, the dosage of metformin in this study needs to be
considered with caution for human applications. We chose 250 mg/kg of metformin based on the
glucose-lowering effect. Although delayed gastric emptying might be part of the response to toxicity of
this dose, no change in dietary intake or body weight was observed in mice treated with 250 mg/kg of
metformin for one week. Furthermore, metformin concentrations in the jejunum can reach levels that
are 30–300-fold higher than those in the plasma [28] or other tissues [29]. These facts suggest that clinical
dosages in humans might have a similar effect. Second, metformin was administered in two doses
(50 or 250 mg/kg/day) with a single administration. The threshold dose for the TG-lowering effect
may be determined by graded experiments between 50 and 250 mg/kg. Multiple administrations
per day also may impact the TG-lowering effect. Third, we have not directly compared a single
administration with an acute effect during chronic administration. The differences in the TG-lowering
effect observed in the acute setting may be attenuated, because chronic administration would promote
a steady state.
In conclusion, single-dose metformin treatment before olive oil-loading significantly reduced
postprandial plasma TG concentrations by delaying gastric emptying. Our results suggest that altered
metformin administration timing without additional medication would represent a novel approach for
enhancing TG-lowering strategies in patients with T2DM and postprandial hypertriglyceridemia.
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4. Materials and Methods
4.1. Materials
All materials were reagent grade and purchased from Nacalai Tesque (Kyoto, Japan) unless
otherwise indicated. Metformin was purchased from Sigma-Aldrich Japan Co. (#D150959, Tokyo, Japan).
Glyceryl-1-13C tripalmitate was obtained from Tsukishima Foods Industry Co., Ltd. (Tokyo, Japan).
4.2. Animals
129S mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Male 129S mice aged
8–11 weeks were used for all experiments. The animals were housed under standard conditions with a
12 h light/dark cycle and free access to water and food. The mice were fed a high-fat diet for three
weeks (HFD; 60% of total calories from fat, Research diets, Inc. (#D12492, New Brunswick, NJ, USA).
All procedures for animal experiments were approved by the Shiga University of Medical Science
Animal Care Committee concerning animal experiments (identification code: 2013-5-3, approval date:
20 May 2013) and animals were treated in accordance with the Guidelines of the United States National
Institutes of Health [30] regarding the care and use of animals for experimental procedures and the
Guidelines of Shiga University of Medical Science for the care and use of laboratory animals.
4.3. Pharmacological Intervention
Metformin was dissolved in water. Mice were given an oral gavage of 50 or 250 mg/kg of
metformin or vehicle (water).
4.4. Body Weight and Food Intake
Mice were housed in pairs, and body weights and food intakes were determined before and after
metformin treatment (50 and 250 mg/kg/day) for one week during the light cycle. Food intake (grams
per day) was measured daily for seven days. Diet for fed mice contained 60% of total calories from fat.
4.5. Oral Glucose Tolerance Test (OGTT)
Glucose (1 g/kg) was administered orally following a 6-h fast. Tail vein bleeds were used to
measure plasma glucose levels at 0, 30, 60, 90, and 120 min after glucose-loading.
Experiment 1: Glucose-lowering effect of different metformin dosages administered for one week
OGTT were examined after one week of metformin treatment (50 mg/kg and 250 mg/kg)
in 129S mice fed a HFD for three weeks. Final administration of metformin was performed 6 h
before glucose-loading.
Experiment 2: Glucose-lowering effect of different timing of single-dose metformin administration
OGTTs were examined at the different administration setting in 129S mice fed a HFD for three
weeks. Metformin (250 mg/kg) was administered 1 h before, concurrently with, and 0.5 h after
glucose loading.
4.6. Oral Lipid Tolerance Test (OLTT)
OLTTs were performed as previously described with a minor modification [31–33]. Briefly, olive
oil (0.4 mL) was administered orally following a 6-h fast. Tail vein bleeds were used to measure plasma
TG at 0, 60, 120, and 180 min after olive oil-loading.
Experiment 1: TG-lowering effect of metformin administration for 1 week
OLTTs were examined after administration of metformin (250 mg/kg) for one week in 129S
mice fed a HFD for three weeks. The final metformin administration was performed 6 h or 1 h
before oil-loading.
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Experiment 2: TG-lowering effect of metformin with different administration periods
To compare the acute and chronic effects of metformin administration on postprandial lipid
metabolism, mice were treated with a single or one-week administration of metformin. The final
metformin administration (250 mg/kg) was performed 1 h before oil loading.
Experiment 3: TG-lowering effect of a single metformin dose with different administration timings
OLTTs were examined in 129S mice fed a HFD for three weeks. Metformin (250 mg/kg) was
administered 1 h before, concurrently with, and 0.5 h after glucose loading.
4.7. ApoB-48 Secretion from Primary Small Intestinal Enterocytes
ApoB secretion from primary small intestinal enterocytes was measured as previously described
with minor modifications [34]. Briefly, olive oil (0.4 mL) was orally administered 1 h after
administration of a single-dose of metformin. The small intestine was extracted and cut into 2 × 2 mm2
fragments. Fragment were incubated in ice cold MatriSperse Cell Recovery Solution (Corning, #354253,
Corning, NY, USA) at 4 ◦C for 8 h without agitation. The obtained fragments were transferred to a
plastic culture dish containing 7 mL of ice-cold MatriSperse Cell Recovery Solution and incubated
at 4 ◦C for 8 h without agitation. The dish was then gently shaken to separate the villi, and the
villi suspension was washed twice in ice-cold PBS (−) (180 g, 5 min). After the final spin, the
villi were resuspended in Dulbecco’s Modified Eagle’s medium with 10% fetal bovine serum and
0.2 U/mL insulin in the culture dishes (1 × 106 cells/well). We measured the amount of apoB-48
(Wako Chemicals Co., #K23300R, Takasaki, Japan) secreted from primary cultured enterocytes into the
medium for 120 min after resuspension. Immunoblotting using an apoB-48 antibody was performed
on the triacylglycerol-rich lipoprotein fractions by SDS-PAGE analysis.
4.8. Analysis of the Actual Ratio of 13CO2 to 12CO2 in Sampled Gas
Preparation of glyceryl-1-13C tripalmitate, sampling of expired gas and analysis of the actual ratio
of 13CO2 to 12CO2 in sampled gas were performed as previously reported [35]. After three weeks of
HFD-feeding, 13C-labeled triacyl palmitic acid (0.4 mL) was administered orally following a 6-h fast
to 129S mice with 1 h pre-treatment of metformin (250 mg/kg) or no medication. The administered
13C-labeled fatty acids were beta oxidized and finally catabolized to 13CO2 in the citric acid cycle in
mitochondria. Therefore, changes in the 13C/12C ratio (∆13C) in expired CO2 from mice indicated the
degree of beta oxidation in the whole body.
4.9. Statistical Analyses
Results are expressed as mean ± SEM. Student’s t test was used for comparisons between
two groups. One way ANOVA and a subsequent post hoc Tukey test were used to determine the
significance of differences for multiple comparisons. p-values < 0.05 were considered statistically
significant. All animal experiments were performed with n = 3–12 as indicated in the individual
figure legends.
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